After hours CHF42.54: BMY.SW Bristol-Myers Squibb SIX Oversold bounce Mar 2026

BMY.SW stock dropped to CHF42.54 in after hours trade on 24 Mar 2026, a -4.40% intraday decline from the previous close. The move left the share price below the 50-day average CHF43.75 and at the year low CHF42.54, creating a classic oversold bounce setup on the SIX (Switzerland). Traders should weigh short-term rebound potential against medium-term model downside. This piece lays out technical triggers, financial ratios, Meyka AI grading, and realistic price targets for an oversold bounce strategy.

BMY.SW stock: price action and immediate levels

Bristol-Myers Squibb (BMY.SW) closed after hours at CHF42.54, down CHF1.96 or -4.40%. Intraday volume showed 500 shares versus an average 22, giving a relative volume of 22.73, which signals focused trading interest. Day low and year low sit at CHF42.54, immediate resistance is the 50-day average CHF43.75, and the next resistance is the year high CHF44.75. A short-term bounce candidate would need a reclaim of CHF43.75 on rising volume to confirm strength.

BMY.SW stock: technicals that support an oversold bounce

Momentum indicators show short-term weakness but potential for mean reversion. MACD reads -0.11 with a signal at -0.04, and ATR is 0.20 CHF, indicating low absolute volatility. ADX is extreme at 100.00, flagging a strong recent trend down. Price sitting at the lower Keltner band (42.59 CHF) suggests a mechanical bounce target back to the middle band (42.99 CHF) and first resistance at 43.75 CHF. Use tight stops; a failure below CHF42.54 increases downside risk.

BMY.SW stock: fundamentals, ratios and sector context

BMY.SW lists on the SIX in Switzerland with market cap CHF70.70B and EPS CHF2.73. Reported PE stands at 15.58, while trailing metrics show a price-to-sales of 1.33 and dividend yield near 3.50%. Debt to equity is elevated at 2.75, with interest coverage of 6.47, reflecting leverage typical of large pharma deals. The Healthcare sector YTD performance is -8.00%, so BMY.SW underperformance fits broader sector trends. These fundamentals support income-focused investors but add volatility for short-term traders.

Meyka AI rates BMY.SW with a score out of 100 and valuation view

Meyka AI rates BMY.SW with a score of 73.59 out of 100 — Grade B+ and suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. The grade is informational only and not financial advice. Key metrics used include free cash flow yield 22.998%, ROE 37.23%, and debt to equity 2.75, which together shape the grade and the buy suggestion.

BMY.SW stock: news, catalysts and trading strategy

No company-specific catalysts were posted today, but sector and dividend coverage headlines remain relevant. Watch upcoming earnings on 2026-04-30 as the primary catalyst for directional conviction. For an oversold bounce strategy: look for a volume-backed reclaim of CHF43.75 for an initial target CHF45.50. A tighter trade could target CHF44.75 with a stop under CHF41.00 to limit downside. Longer-term investors should monitor balance sheet deleveraging and pipeline updates.

BMY.SW stock: model forecasts and risk profile

Meyka AI’s forecast model projects CHF39.34 for the next year, which implies -7.52% versus the current CHF42.54. Three-year and five-year model points sit at CHF30.91 and CHF22.55 respectively, reflecting conservative longer-term outputs. Forecasts are model-based projections and not guarantees. Key risks include litigation, patent cliffs, and high leverage. Upside catalysts include stronger-than-expected earnings, positive trial readouts, or M&A synergy realisation.

Final Thoughts

BMY.SW stock shows a short-term oversold bounce setup after an after hours close at CHF42.54, down -4.40% on concentrated volume. Technicals point to a possible quick snap-back to CHF43.75 or CHF44.75, with a pragmatic short-term target of CHF45.50 (+6.96%). Meyka AI’s rating assigns a B+ (BUY) grade and the model projects CHF39.34 over the next year, implying -7.52% versus the current price. That divergence frames our trade idea: nimble traders can look for a volume-backed reclaim of CHF43.75 and keep stops near CHF41.00. Longer-term investors should weigh the company’s cash flow strength and dividend yield against its elevated debt. These takeaways combine technical triggers with Meyka AI-powered market analysis to set clear entry, target, and stop levels, while acknowledging model and execution risk.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.